By: Schoolcraft H.B. No. 1319

A BILL TO BE ENTITLED

1	73.73.7	7 0 0
l .	ΔΝ	ACT
		$\Delta C \perp$

- 2 relating to wholesale importation of prescription drugs in this
- 3 state.
- 4 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
- 5 SECTION1. Subtitle A, Title 6, Chapter 444 Health and Safety Code,
- 6 is amended as follows:
- 7 CHAPTER 444. WHOLESALE PRESCRIPTION DRUG IMPORTATION PROGRAM
- 8 Sec. 444.001. DEFINITIONS. In this chapter:
- 9 (1) "Canadian supplier" means a manufacturer,
- 10 wholesale distributor, or pharmacy that is appropriately licensed
- 11 or permitted under Canadian federal or provincial laws and rules to
- 12 manufacture, distribute, or dispense prescription drugs.
- 13 (2) "European Union supplier" " means a manufacturer,
- 14 wholesale distributor, or pharmacy that is appropriately licensed
- 15 or permitted under European Union or laws and rules, or the national
- 16 laws and rules of a European Union member nation, to manufacture,
- 17 distribute, or dispense prescription drugs.
- 18 $(\frac{23}{})$ "Commission" means the Health and Human Services
- 19 Commission.
- 20 $(\frac{34}{2})$ "Prescription drug wholesaler" means a person
- 21 licensed as a wholesale distributor under Subchapter N, Chapter
- 22 431, that contracts with this state to import prescription drugs
- 23 under the program.
- 24 (45) "Program" means the wholesale prescription drug

- 1 importation program established under this chapter.
- 2 Sec. 444.002. ESTABLISHMENT OF WHOLESALE PRESCRIPTION DRUG
- 3 IMPORTATION PROGRAM. (a) The commission shall establish the
- 4 wholesale prescription drug importation program to provide lower
- 5 cost prescription drugs available outside of the United States to
- 6 consumers in this state at the lower cost.
- 7 (b) The commission shall implement the program by:
- 8 (1) contracting with one or more prescription drug
- 9 wholesalers and Canadian or European Union suppliers to import
- 10 prescription drugs and provide prescription drug cost savings to
- 11 consumers in this state;
- 12 (2) developing a registration process for health
- 13 benefit plan issuers, health care providers, and pharmacies to
- 14 obtain and dispense prescription drugs imported under the program;
- 15 (3) developing a list of prescription drugs, including
- 16 the prices of those drugs, that meet the requirements of Section
- 17 444.003 and publishing the list on the commission's Internet
- 18 website;
- 19 (4) establishing an outreach and marketing plan to
- 20 generate program awareness;
- 21 (5) establishing and administering a telephone call
- 22 center or electronic portal to provide information about the
- 23 program;
- 24 (6) ensuring the program and the prescription drug
- 25 wholesalers that contract with this state under Subdivision (1)
- 26 comply with the tracking, tracing, verification, and
- 27 identification requirements of 21 U.S.C. Section 360eee-1;

H.B. No. 1319

- 1 (7) prohibiting the distribution, dispensing, or sale
- 2 of prescription drugs imported under this chapter outside the
- 3 boundaries of this state; and
- 4 (8) performing any other duties the executive
- 5 commissioner determines necessary to implement the program.
- 6 (c) The commission shall ensure that the program meets the
- 7 requirements of 21 U.S.C. Section 384.
- 8 (d) In developing the program, the commission may consult
- 9 with interested parties.
- 10 Sec. 444.003. ELIGIBLE PRESCRIPTION DRUGS. A prescription
- 11 drug may be imported into this state under the program only if the
- 12 drug:
- 13 (1) meets the United States Food and Drug
- 14 Administration's standards related to prescription drug safety,
- 15 effectiveness, misbranding, and adulteration;
- 16 (2) does not violate any federal patent laws through
- 17 its importation;
- 18 (3) is expected to generate cost savings for
- 19 consumers; and
- 20 (4) is not:
- 21 (A) listed as a controlled substance under state
- 22 or federal law;
- 23 (B) a biological product;
- 24 (C) an infused drug;
- 25 (D) an intravenously injected drug;
- 26 (E) a drug that is inhaled during surgery; or
- 27 (F) a parenteral drug.

H.B. No. 1319

- 1 Sec. 444.004. ANTICOMPETITIVE BEHAVIOR MONITORING. The
- 2 commission, in consultation with the attorney general, shall
- 3 identify and monitor any potential anticompetitive activities in
- 4 industries affected by the program.
- 5 Sec. 444.005. PROGRAM FUNDING. In addition to money
- 6 appropriated by the legislature, the commission may impose a fee on
- 7 each prescription drug sold under the program or establish another
- 8 funding method to administer the program.
- 9 Sec. 444.006. AUDIT PROCEDURES. The executive commissioner
- 10 by rule shall develop procedures to effectively audit a
- 11 prescription drug wholesaler participating in the program.
- 12 Sec. 444.007. ANNUAL REPORTING. Not later than December 1
- 13 of each year, the commission shall submit a report to the governor
- 14 and the legislature regarding the operation of the program during
- 15 the preceding state fiscal year, including:
- 16 (1) which prescription drugs and <u>Canadian or European</u>
- 17 Union suppliers are included in the program;
- 18 (2) the number of health benefit plan issuers, health
- 19 care providers, and pharmacies participating in the program;
- 20 (3) the number of prescriptions dispensed through the
- 21 program;
- 22 (4) the estimated cost savings to consumers, health
- 23 plans, employers, and this state since the establishment of the
- 24 program and during the preceding state fiscal year;
- 25 (5) information regarding the implementation of the
- 26 audit procedures under Section 444.006; and
- 27 (6) any other information:

H.B. No. 1319

- 1 (A) the governor or the legislature requests; or
- 2 (B) the commission considers necessary.
- 3 SECTION 3. This Act takes effect September 1, 2025.